CS MEDICA Announces Strategic Partnerships to Enhance Funding
Securing New Capital and Strengthening Shareholder Relations Through Strategic Collaborations
CS MEDICA, a pioneering MedTech company specializing in pain management and autoimmune diseases with innovative substance-based medical devices containing bioactive CBD, announces a direct issue of 1.5 MDKK with Börsjakten AB at a share price of 3.00 DKK. This initiative is part of our broader strategy to secure short-term capital while preparing for a larger funding round, pending approval at the upcoming EGM. Additionally, we are excited to unveil three strategic collaborations aimed at enhancing shareholder engagement and increasing market capitalization.
Börsjakten AB Collaboration: This partnership will launch a stock competition, "Börsjakten," to attract new shareholders and boost publicity and awareness through influential finance and economics influencers.
IPO Invest Sweden AB Partnership: This collaboration focuses on enhancing CS MEDICA's investor relations strategy to strengthen shareholder value and engagement.
Novtec AB Agreement: Novtec AB will assist in securing investment capital ensuring CS MEDICA has the necessary funds for strategic growth initiatives.
These partnerships underscore CS MEDICA's commitment to innovation, growth, and delivering value to stakeholders.
For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally.
The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.
CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes.
Tags: